KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,029 | +7.0% | 1,353 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $12,177 | +14.5% | 1,353 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $10,635 | +2.5% | 1,353 | -11.9% | 0.00% | – |
| Q4 2022 | $10,377 | -48.0% | 1,535 | +11.7% | 0.00% | -100.0% |
| Q3 2022 | $19,937 | +47.5% | 1,374 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $13,520 | -33.2% | 1,374 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $20,253 | -71.0% | 1,374 | -73.9% | 0.00% | 0.0% |
| Q4 2021 | $69,775 | -24.2% | 5,274 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $92,031 | -23.8% | 5,274 | +4.7% | 0.00% | -50.0% |
| Q2 2021 | $120,710 | -6.7% | 5,038 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $129,426 | +38.1% | 5,038 | +2.1% | 0.00% | +100.0% |
| Q4 2020 | $93,697 | +326.4% | 4,934 | +397.4% | 0.00% | – |
| Q2 2019 | $21,972 | – | 992 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |